Paracetamol 500mg Tablets

DRUG4 trials

Sponsors

F. Hoffmann-La Roche AG, Regeneron Pharmaceuticals Inc.

Conditions

Primary Progressive Multiple Sclerosis (PPMS)Relapsed or Refractory Systemic Light Chain AmyloidosisRelapsing Multiple Sclerosis (MS)Relapsing-Remitting Multiple Sclerosis (RRMS)

Phase 1

A Phase 1/2 Study of Linvoseltamab in Patients with Relapsed or Refractory Systemic Light Chain Amyloidosis

RecruitingCTIS2023-507809-34-00

Regeneron Pharmaceuticals Inc.Relapsed or Refractory Systemic Light Chain Amyloidosis

Start: 2024-08-07Target: 27Updated: 2025-09-24

Phase 2

An Open-Label, Parallel-Group Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of Ocrelizumab in Children and Adolescents with Relapsing-Remitting Multiple Sclerosis

Active, not recruitingCTIS2023-507313-94-00

F. Hoffmann-La Roche AGRelapsing-Remitting Multiple Sclerosis (RRMS)

Start: 2019-10-18Target: 12Updated: 2025-09-12

Phase 3

A Phase IIIb Multicenter, Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis

Active, not recruitingCTIS2023-506467-34-00

F. Hoffmann-La Roche AGRelapsing Multiple Sclerosis (MS)

Start: 2020-10-20Target: 357Updated: 2025-11-17

A Phase IIIB Multicenter, Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults with Primary Progressive Multiple Sclerosis

Active, not recruitingCTIS2023-506515-18-00

F. Hoffmann-La Roche AGPrimary Progressive Multiple Sclerosis (PPMS)

Start: 2020-10-23Target: 310Updated: 2025-03-26